Allogene Therapeutics ALLO Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's operating lease liabilities (total)?
- Allogene Therapeutics (ALLO) reported operating lease liabilities (total) of $81.05M in Q1 2026.
- How has Allogene Therapeutics's operating lease liabilities (total) changed year-over-year?
- Allogene Therapeutics's operating lease liabilities (total) decreased by 8.9% year-over-year, from $88.92M to $81.05M.
- What is the long-term trend for Allogene Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Allogene Therapeutics's operating lease liabilities (total) has grown at a 9.1% compound annual growth rate (CAGR), from $53.78M to $83.25M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.